What Is Retatrutide? Benefits, Research & Safety
An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in Phase 2 trials—potentially the most potent obesity treatment in development.
UK summary: Investigational compound. Not yet a licensed UK medicine. Phase 2 human data are promising for weight loss but Phase 3 results and regulatory review are still required. Any 'retatrutide' offered for sale outside a registered clinical trial is grey-market.
Quick Facts
Overview
Retatrutide — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Investigational compound. Not yet a licensed UK medicine. Phase 2 human data are promising for weight loss but Phase 3 results and regulatory review are still required. Any 'retatrutide' offered for sale outside a registered clinical trial is grey-market.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: NOT APPROVED. Investigational compound. May be available only through clinical trial participation.
- EU: NOT APPROVED. Investigational compound in Phase 3 clinical trials.
- Notes: ⚠️ IMPORTANT: Retatrutide is NOT approved by any regulatory authority for any indication. It is currently in Phase 3 clinical trials. Any products sold online claiming to be retatrutide are likely counterfeit, unverified, and potentially dangerous. Do not purchase from unregulated sources.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- The most effective GLP-1 ever made — buy now before it's prescription-only.
- Triple agonist means triple the fat loss in half the time.
- Sold as 'research-grade retatrutide' identical to the Eli Lilly compound.
- Safe for self-administration at home, no doctor needed.
07Common internet claims
- Pre-launch access to the next-generation Mounjaro.
- 24% bodyweight loss guaranteed by 48 weeks.
- Cheaper than waiting for the licensed version.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved by MHRA for weight loss” | E | No | High | Retatrutide is investigational and not licensed in the UK at the time of writing. |
| “Phase 2 trials showed ~24% weight loss” | B | Yes | Low | Phase 2 data show high mean weight loss; Phase 3 confirmation and regulatory review are required before clinical use. |
| “Available now from research peptide suppliers” | E | No | High | Any vendor selling 'retatrutide' is operating outside the regulated UK supply chain. Identity and purity are unverified. |
| “Safe to self-administer for personal use” | E | No | High | Long-term safety has not been established. Self-administration of an investigational compound carries serious risk. |
09Safety uncertainty score
Effectively no human safety data; safety claims are extrapolations from animal work or anecdote.
10Known adverse signals
- Nausea, vomiting, diarrhoea, constipation, dyspepsia at trial doses.
- Pancreatitis risk (class signal across incretin agonists).
- Unknown chronic effects of sustained glucagon receptor activation.
- Long-term cardiovascular and oncologic data not yet available.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
NOT APPROVED. Investigational compound. May be available only through clinical trial participation.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
NOT APPROVED. Investigational compound in Phase 3 clinical trials.
15What this page cannot tell you
- Whether a vial sold online actually contains retatrutide rather than a relabelled tirzepatide or a placebo.
- What the long-term safety profile looks like beyond the 48-week Phase 2 horizon.
- How a grey-market compound interacts with insulin, sulfonylureas, or other glucose-lowering drugs.
- Whether the manufacturing process matches sterile injectable standards.
16Last reviewed
17Citation quality score
18Research gaps
- Phase 3 outcomes (TRIUMPH programme) not yet published in full.
- Cardiovascular outcome trial data pending.
- Long-term safety of chronic glucagon receptor agonism unknown.
- Real-world post-marketing surveillance impossible — drug is not licensed.
19Safer alternatives / established care pathways
- Licensed Wegovy (semaglutide) via NHS or GMC-registered prescriber.
- Licensed Mounjaro (tirzepatide) via NHS specialist or registered private clinic.
- Enrolment in a registered TRIUMPH-programme Phase 3 trial via ClinicalTrials.gov.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What is the current MHRA status of retatrutide?
- Are there any UK clinical trials I might be eligible for?
- What licensed alternatives exist for my situation today (semaglutide, tirzepatide)?
- Why is buying retatrutide from an online seller a risk even compared with other peptides?
- How would suspected adverse events from any product be reported?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Weight loss of 24.2% at highest dose in Phase 2—potentially the most effective pharmaceutical weight loss
- 226% of participants achieved ≥30% weight loss (matching surgical outcomes)
- 3Significant reductions in liver fat (up to 86% reduction in hepatic steatosis)
- 4Substantial improvements in glycaemic control in participants with diabetes
- 5Marked reductions in waist circumference
- 6Improvements in blood pressure and lipid profiles
- 7High proportion achieving metabolically healthy weight status
- 8Potential disease-modifying effects on NAFLD/NASH
- 9Maintained glucose control despite glucagon agonism
Claim vs Evidence
How popular claims about Retatrutide stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Approved by MHRA for weight loss” | E | No | High | Retatrutide is investigational and not licensed in the UK at the time of writing. |
| “Phase 2 trials showed ~24% weight loss” | B | Yes | Low | Phase 2 data show high mean weight loss; Phase 3 confirmation and regulatory review are required before clinical use. |
| “Available now from research peptide suppliers” | E | No | High | Any vendor selling 'retatrutide' is operating outside the regulated UK supply chain. Identity and purity are unverified. |
| “Safe to self-administer for personal use” | E | No | High | Long-term safety has not been established. Self-administration of an investigational compound carries serious risk. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Phase 2 studied doses up to 12mg weekly; exact dosing for approval TBD |
| Frequency | Once weekly subcutaneous injection (in trials) |
| Duration | Phase 2 was 48 weeks; long-term data awaited from Phase 3 |
| Notes | ⚠️ RETATRUTIDE IS NOT APPROVED FOR ANY USE. It is an investigational compound in Phase 3 clinical trials. The information above is from research publications and does not represent prescribing guidance. Do NOT attempt to obtain retatrutide from unregulated sources. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (investigational—once weekly in trials)
| Half-Life | Stability |
|---|---|
| Approximately 6 days (estimated from Phase 2 data) | Not applicable—investigational compound not commercially available |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea (most common, similar to other incretin therapies)
- Diarrhoea
- Vomiting
- Constipation
- Decreased appetite
- Dyspepsia
- Abdominal pain
- Injection site reactions
Rare Risks & Concerns
- Pancreatitis (theoretical risk with all incretin therapies)
- Gallbladder disease (accelerated by rapid weight loss)
- Thyroid C-cell tumours (theoretical—class warning)
- Unknown long-term risks (limited Phase 2 data)
- Potential cardiovascular effects (being evaluated in trials)
- Unknown effects of chronic glucagon receptor activation
Contraindications
- This is an INVESTIGATIONAL compound—not approved for any use
- Should only be used within clinical trial settings
- Presumed contraindications similar to GLP-1 agonists:
- - Personal/family history of medullary thyroid carcinoma
- - Multiple Endocrine Neoplasia syndrome type 2
- - Pregnancy and breastfeeding
- - Type 1 diabetes
- - History of pancreatitis
UK & EU Regulatory Context
🇬🇧 United Kingdom
NOT APPROVED. Investigational compound. May be available only through clinical trial participation.
🇪🇺 European Union
NOT APPROVED. Investigational compound in Phase 3 clinical trials.
Clinical Studies Summary
Phase 2 Retatrutide Trial
Landmark Phase 2 study showing dose-dependent weight loss up to 24.2% at 12mg dose over 48 weeks. 26% of participants lost ≥30% body weight. Gastrointestinal side effects were common but manageable.
Retatrutide Effects on Hepatic Steatosis
Substudy showing retatrutide reduced liver fat by up to 86% from baseline, with 93% of participants achieving resolution of hepatic steatosis at the highest dose.
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis.
Retatrutide achieved the most pronounced weight reduction, followed by tirzepatide. GLP-1RAs also significantly improved glycemic control for patients with T2D, with tirzepatide performing the best for glycemic control.
Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis.
Multi-receptor drugs demonstrated substantial therapeutic potential in weight management, glycemic control, and blood pressure regulation in adults with overweight or obesity, with or without diabetes, with a generally favorable safety profile.
Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis.
Females lost more weight than males when treated with GLP-1RAs for weight reduction. The sex difference in weight reduction became more pronounced as the degree of weight reduction increased. Indications for obesity could magnify this sex difference.
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.
GLP-1RAs decreased liver fat deposition and improved histological steatosis, hepatocellular ballooning, and lobular inflammation, without worsening of fibrosis in MASLD and MASH. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints.
Registered Trials & Regulatory Status
18 of 20 completed trials have never posted results. Unreported trials are not neutral: results that go unpublished are more often negative ones.
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
Status: Recruiting · 300 participants · Hudson Biotech
Conditions: Obesity
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Status: Active Not Recruiting · 600 participants · Eli Lilly and Company
Conditions: Obesity, Overweight
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Status: Active Not Recruiting · 250 participants · Eli Lilly and Company
Conditions: Obesity, Overweight
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Status: Recruiting · 4,500 participants · Eli Lilly and Company
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Status: Completed · 80 participants · Eli Lilly and Company
Conditions: Type 2 Diabetes Mellitus
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Status: Recruiting · 95 participants · Eli Lilly and Company
Conditions: Diabetes Mellitus, Insulin Sensitivity
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Status: Recruiting · 586 participants · Eli Lilly and Company
Conditions: Obesity, Overweight, Chronic Low Back Pain (CLBP)
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Status: Active Not Recruiting · 643 participants · Eli Lilly and Company
Conditions: Obesity
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
Status: Completed · 30 participants · Eli Lilly and Company
Conditions: Healthy
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Status: Active Not Recruiting · 800 participants · Eli Lilly and Company
Conditions: Obesity
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Status: Active Not Recruiting · 10,000 participants · Eli Lilly and Company
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Status: Completed · 537 participants · Eli Lilly and Company
Conditions: Diabetes Type 2
Adverse event reports (FDA FAERS)
Not applicable: no licensed product contains this peptide, so it is not reported through FAERS. This is an absence of surveillance, not evidence of safety.
Source: ClinicalTrials.gov and openFDA. Updated automatically.
Looking for Retatrutide?
Source research-grade Retatrutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Retatrutide
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- What is the current MHRA status of retatrutide?
- Are there any UK clinical trials I might be eligible for?
- What licensed alternatives exist for my situation today (semaglutide, tirzepatide)?
- Why is buying retatrutide from an online seller a risk even compared with other peptides?
- How would suspected adverse events from any product be reported?
UK regulatory & safety context
Related Research Guides
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreGLP-1
A naturally occurring gut hormone that regulates glucose metabolism and appetite, serving as the basis for major obesity and diabetes medications.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn more